Celyad Oncology SA

Add to watchlist
€3.37
Last updated:07/30/2021
1C0: F
Celyad Oncology SA

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Ph… Show more

P/E ratio
-
vs. 0.00x forward

Company has negative earnings per share so P/E ratio is not available.

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
Create free account to unlock
Cashflow
Sum up money going in and out company
Create free account to unlock
Total liabilities
All combined debts and obligations
Create free account to unlock
Company profile
CEO
Mr. Filippo Joseph Petti
Market capitalization
Nano (41.10M)